Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less
Identifying Factors That Improve The Health Of Prisoners Who Inject Drugs
Funder
National Health and Medical Research Council
Funding Amount
$376,658.00
Summary
Prisoners who inject drugs are highly marginalised with high rates of unresolved health and social issues and high rates of return to prison. Little is known, however, about how this group manages after release from prison. This qualitative project will allow ex-prisoners to tell their own stories of the challenges they have had and what strategies (formal and informal) they have used with the aim of informing responses in prisons and in the community setting.
Epilepsy is one of the most common chronic neurological disorders; it affects 1% of the world’s population, yet about 1 in 3 patients fail to achieve seizure control with current drugs. We will improve the properties of small molecules (drugs) that specifically target the GTPase activity of the enzyme dynamin, to reduce seizure effect in the brain by a novel mechanism. We will optimize and pre-clinically test these future chemical entities as potential anti-epileptic drugs.
Predicting Drug-drug Interactions Due To Tyrosine Kinase Inhibitors: Inhibition Of Drug Metabolising Enzymes And Transporters
Funder
National Health and Medical Research Council
Funding Amount
$535,495.00
Summary
Tyrosine kinase inhibitors (TKIs) are a new class of anticancer agents. Cancer patients typically receive multiple drugs, for the treatment of cancer and other diseases, increasing the probability of interactions between coadministered drugs. Despite the widespread use of TKIs, their potential to cause drug interactions is poorly understood. Using novel in vitro approaches, this project will identify drug interactions precipitated by TKIs thereby improving drug efficacy and patient safety.
Development Of A New High Throughput Screen For Drug Binding To HERG K+ Channels
Funder
National Health and Medical Research Council
Funding Amount
$351,320.00
Summary
Inadvertent drug block of hERG, a potassium channel in the heart, can cause cardiac arrhythmias and sudden cardiac death. Screening for hERG toxicity has become a major hurdle for development of new drugs. We will use a mutant hERG protein that has enhanced drug binding to develop a high throughput test for hERG toxicity. Identification of dangerous drugs early in the drug discovery process will save the pharmaceutical industry millions of dollars in the costs of brining new drugs to market.
Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.
In 2013 there were ~200 million clinical cases of malaria, causing ~600,000 deaths. All antimalarial drugs are now associated with malaria parasite resistance. Thus, new therapies are urgently needed, including new drugs to prevent this disease. We have made the exciting discovery that an existing antimalarial drug can kill malaria parasites in a unique, previously unknown, manner. Here, we will investigate how this occurs and develop new drug candidates for malaria prevention.